“The exclusive license of patents from UC Irvine has the potential for NeuroQure to bring medical diagnostic tools validated with top-tier publications and issued patents as a functional biomarker diagnostic for the broad ASD spectrum from the lab to market, enabling early intervention and improving children’s lives,” said David Justus, NeuroQure’s Founder and CEO.